Connect Biopharma Holdings Limited (CNTB) Discusses Rademikibart and SEABREEZE Trial Results in Acute COPD TranscriptSeeking Alpha · 2 days ago
Down 25.4% in 4 Weeks, Here's Why Connect Biopharma Holdings (CNTB) Looks Ripe for a TurnaroundZacks Investment Research · 3 days ago
Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom FisherZacks Investment Research · 6 days ago
Connect Biopharma (NASDAQ:CNTB) & Inhibrx Biosciences (NASDAQ:INBX) Critical ContrastDefense World · Oct 5, 2026
Connect Biopharma COPD Study Shows 81% Cut in Treatment FailuresMarketBeat · Oct 4, 2026
Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD TherapyBenzinga · Sep 30, 2026Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.31 | -$0.27 | Beat |
| May 12, 2026 | -$0.29 | -$0.34 | Miss |
| Mar 31, 2026 | -$0.30 | -$0.27 | Beat |
| Nov 12, 2025 | -$0.03 | -$0.04 | Miss |
| Aug 13, 2025 | -$0.22 | -$0.03 | Beat |
| May 15, 2025 | -$0.26 | -$0.03 | Beat |